Harvard Bioscience (HBIO) Inventory Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Inventory Average data on file, last reported at $21.5 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $21.5 million, down 6.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.5 million (down 6.62% YoY), and the FY2025 annual result was $22.0 million, down 8.15% from the prior year.
• Inventory Average climbed to $21.5 million in Q1 2026 per HBIO's latest filing, from $21.2 million in the prior quarter.
• Over five years, Inventory Average peaked at $29.0 million in Q2 2022 and troughed at $21.2 million in Q4 2025.
• A 5-year average of $25.0 million and a median of $25.3 million in 2023 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2022 and 2025: Inventory Average advanced 25.28% in 2022, then fell 14.2% in 2025.
• A 5-year view of Inventory Average shows it stood at $26.3 million in 2022, then dropped by 3.85% to $25.3 million in 2023, then declined by 2.57% to $24.6 million in 2024, then declined by 13.86% to $21.2 million in 2025, then grew by 1.42% to $21.5 million in 2026.
• Business Quant data shows HBIO's Inventory Average at $21.5 million in Q1 2026, $21.2 million in Q4 2025, and $21.9 million in Q3 2025.